Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on April 9, 2019, reporting events occurring on April 4, 2019. The Company is a Delaware corporation headquartered in Bothell, Washington.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
On April 4, 2019, the Board of Directors appointed Dr. Anthony Japour as a director to fill a vacancy, effective immediately. This appointment was designated by Dr. Raymond Schinazi, the Company's principal stockholder, pursuant to a Stockholder Rights Agreement dated November 24, 2014. Dr. Japour was also appointed to the Compensation Committee and the Corporate Governance and Nominating Committee.
Management Commentary and Risks
Dr. Japour brings experience as a Medical Director at ICON plc since February 2016 and previously as an internal medicine physician specializing in infectious diseases. The filing explicitly states there are no related party transactions between the Company and Dr. Japour reportable under Item 404(a) of Regulation S-K. No other risks, contingencies, or unusual items are disclosed in this document.
Investor Verification Checklist
- Verify the terms of the Stockholder Rights Agreement dated November 24, 2014, regarding Dr. Schinazi's designation rights.
- Confirm Dr. Japour's current roles and potential conflicts of interest with ICON plc.
- Review the Company's most recent 10-K or 10-Q for financial performance data not included in this 8-K.